A metanalysis by Zhang et al. showed that the presence of CDKN2A/2B deletion was associated with adverse OS and EFS outcomes in both pediatric and adult ALL patients [266]. This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.